[go: up one dir, main page]

CA2319565A1 - Compositions pharmaceutiques se presentant sous forme de nanoparticules comprenant des substances lipidiques et des substances amphiphiles, et procede de preparation connexe - Google Patents

Compositions pharmaceutiques se presentant sous forme de nanoparticules comprenant des substances lipidiques et des substances amphiphiles, et procede de preparation connexe Download PDF

Info

Publication number
CA2319565A1
CA2319565A1 CA002319565A CA2319565A CA2319565A1 CA 2319565 A1 CA2319565 A1 CA 2319565A1 CA 002319565 A CA002319565 A CA 002319565A CA 2319565 A CA2319565 A CA 2319565A CA 2319565 A1 CA2319565 A1 CA 2319565A1
Authority
CA
Canada
Prior art keywords
nanoparticles
compositions
microemulsion
composite
composite material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319565A
Other languages
English (en)
Inventor
Pierandrea Esposito
Italo Colombo
Nicoletta Coceani
Maria Dorly Del Curto
Fabio Carli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319565A1 publication Critical patent/CA2319565A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques se présentant sous forme de nanoparticules comprenant un matériau composite constitué d'au moins une substance lipidique et d'au moins une substance amphiphile, et d'un principe pharmaceutiquement actif. Ces compositions, grâce aux propriétés de surface et de masse du matériau composite, présentent une amélioration dans l'incorporation des principes actifs et un accroissement de la biodisponibilité des principes actifs à faible pouvoir d'absorption.
CA002319565A 1998-02-06 1999-02-05 Compositions pharmaceutiques se presentant sous forme de nanoparticules comprenant des substances lipidiques et des substances amphiphiles, et procede de preparation connexe Abandoned CA2319565A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT98MI000234A IT1298575B1 (it) 1998-02-06 1998-02-06 Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
ITMI98A000234 1998-02-06
PCT/EP1999/000782 WO1999039700A1 (fr) 1998-02-06 1999-02-05 Compositions pharmaceutiques se presentant sous forme de nanoparticules comprenant des substances lipidiques et des substances amphiphiles, et procede de preparation connexe

Publications (1)

Publication Number Publication Date
CA2319565A1 true CA2319565A1 (fr) 1999-08-12

Family

ID=11378856

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319565A Abandoned CA2319565A1 (fr) 1998-02-06 1999-02-05 Compositions pharmaceutiques se presentant sous forme de nanoparticules comprenant des substances lipidiques et des substances amphiphiles, et procede de preparation connexe

Country Status (8)

Country Link
EP (1) EP1051160A1 (fr)
JP (1) JP2002502813A (fr)
KR (1) KR20010040726A (fr)
AU (1) AU747129B2 (fr)
BR (1) BR9907683A (fr)
CA (1) CA2319565A1 (fr)
IT (1) IT1298575B1 (fr)
WO (1) WO1999039700A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
RU2246293C2 (ru) 1999-06-14 2005-02-20 Космо С.П.А. Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1214928A4 (fr) * 1999-08-18 2004-03-24 Kyowa Hakko Kogyo Kk Stimulants pour la pousse de cheveux
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
CZ299726B6 (cs) * 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
US6632671B2 (en) * 2000-02-28 2003-10-14 Genesegues, Inc. Nanoparticle encapsulation system and method
ATE389455T1 (de) 2000-05-10 2008-04-15 Jagotec Ag Zerkleinerung mittels mahlkörper
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
KR100508695B1 (ko) * 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US6855270B2 (en) * 2001-06-07 2005-02-15 The University Of Kentucky Research Foundation Nanoscintillation systems for aqueous-based liquid scintillation counting
KR100593861B1 (ko) * 2001-09-24 2006-06-30 한국과학기술원 칼시토닌을 함유한 경구투여용 나노입자의 제조방법
CN1558755A (zh) * 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US9308220B2 (en) 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
WO2003051385A1 (fr) * 2001-12-14 2003-06-26 Jagotec Ag Formulation pharmaceutique contenant de la ciclosporine et son utilisation
SE0104421D0 (sv) 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
KR100422763B1 (ko) * 2002-01-17 2004-03-12 주식회사 태평양 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR20040084240A (ko) * 2003-03-27 2004-10-06 (주) 코스메디 고형지질나노입자, 이를 함유하는 활성성분 전달용약학조성물 및 이의 제조방법
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
WO2005016386A1 (fr) * 2003-08-19 2005-02-24 Meditech Research Limited Protocoles therapeutiques ameliores
JP2007522079A (ja) * 2003-10-31 2007-08-09 エラン ファーマ インターナショナル リミテッド ニメスリド組成物
US20080249076A1 (en) * 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
US7803366B2 (en) 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
EP1674077A1 (fr) * 2004-12-27 2006-06-28 Université de Liège Formulation muco-adhésive refermant des chemokine
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8252326B2 (en) 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
EP2086513B1 (fr) * 2006-09-26 2016-09-07 Samyang Biopharmaceuticals Corporation Nanoparticule submicronique de dérivés de camptothécine faiblement solubles dans l'eau et son procédé de préparation
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US20090087490A1 (en) 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
FR2943545B1 (fr) * 2009-03-31 2011-06-03 Univ Claude Bernard Lyon Nanoparticules lipidiques solides encapsulant du minoxidil et suspension aqueuse les contenant.
WO2011037623A1 (fr) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
FR2958150B1 (fr) 2010-04-01 2012-06-15 Univ Claude Bernard Lyon Elements orthodontiques elastiques aptes a liberer de la chlorhexidine faiblement soluble dans la salive
CN102247320B (zh) * 2010-05-21 2013-03-13 天津药物研究院 一种依托泊苷长循环乳剂及其制备方法
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
FR2995222B1 (fr) 2012-09-11 2016-05-20 Creathes Procede alternatif de microencapsulation de principe actif
EP2919767B1 (fr) * 2012-11-14 2020-04-01 Abon Pharmaceuticals, LLC Système d'administration d'un médicament par voie orale transmuqueuse
CN102988285B (zh) * 2012-12-13 2014-02-19 哈药集团技术中心 一种多西他赛注射液组合物及其制备方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2014282762B2 (en) * 2013-06-20 2016-11-10 Ichnos Sciences SA Nanoparticulate formulation comprising a TRPA1 antagonist
EP2821077A1 (fr) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Nanoparticules lipidiques pour la cicatrisation des plaies
CA2947767A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif
HUE061928T2 (hu) 2014-06-11 2023-09-28 SpecGx LLC Különbözõ oldódási profillal rendelkezõ porlasztva szárított készítmények és elõállításukhoz szükséges eljárások
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
WO2016016861A1 (fr) * 2014-08-01 2016-02-04 Glenmark Pharmaceuticals S.A. Formulation nanoparticulaire comprenant un inhibiteur de mpges -1
CN107072963B (zh) 2014-09-03 2020-07-07 吉倪塞思公司 治疗性纳米粒子和相关的组合物、方法和系统
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
WO2017173071A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
CA3024479A1 (fr) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Polypeptides selectifs du recepteur du glucagon et methodes pour les employer
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
EP3999043A4 (fr) * 2019-07-19 2023-06-21 SPI Pharma, INC. Préparation d'ingrédients actifs lipophiles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
CA2091152C (fr) * 1993-03-05 2005-05-03 Kirsten Westesen Particules lipidiques solides, particules d'agents bioactifs, et methode de preparation et d'utilisation

Also Published As

Publication number Publication date
AU2723899A (en) 1999-08-23
JP2002502813A (ja) 2002-01-29
EP1051160A1 (fr) 2000-11-15
IT1298575B1 (it) 2000-01-12
KR20010040726A (ko) 2001-05-15
BR9907683A (pt) 2000-11-14
WO1999039700A1 (fr) 1999-08-12
AU747129B2 (en) 2002-05-09
ITMI980234A1 (it) 1999-08-06

Similar Documents

Publication Publication Date Title
AU747129B2 (en) Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
JP4865937B2 (ja) パクリタキセル製剤
JP4837809B2 (ja) 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法
EP3280448B1 (fr) Formulations lipidiques d'acétate d'abiratérone
US20030072798A1 (en) Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
US20100291200A1 (en) Formulations for poorly soluble drugs
Bansal et al. Solid self-nanoemulsifying delivery systems as a platform technology for formulation of poorly soluble drugs
US7919113B2 (en) Dispersible concentrate lipospheres for delivery of active agents
WO2005065652A9 (fr) Composition non aqueuse pour une administration orale d'agents bioactifs non solubles
AU763945B2 (en) Oil-core compositions for the sustained release of hydrophobic drugs
HU188099B (en) Process for producing microcapsules of biologically degradable lipide materials localisable magnetically
CN101163464A (zh) 优选含有PEG和PLG混合物的控制释放GnRH的聚合物植入物
WO2009092291A1 (fr) Système d'administration de médicament, son procédé de préparation et d'utilisation
US20050037073A1 (en) Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
CN1092646A (zh) 含有效成分的冻干乳液
CA2443461A1 (fr) Compositions pharmaceutiques contenant des principes actifs anti-inflammatoires et utilisation desdites compositions
KR101180181B1 (ko) 나노 입자 및 그의 제조 방법
Rasiel et al. Phospholipid coated poly (lactic acid) microspheres for the delivery of LHRH analogues
Kamra et al. Topical liposomal gel: A review
Parmar et al. SMEDDS: A dominant dosage form which improve bioavailability
MX2007007887A (es) Sistema galenico novedoso para transporte del principio activo, metodo de preparacion y uso.
JP5684440B2 (ja) 組成物および固形製剤
Jansen et al. Encapsulation to deliver topical actives
Jabbar et al. Formulation and evaluation of antiretroviral drug loaded unsaturated phospholipid based stealth liposome
Verma et al. Solid-SMEDDS: Techniques of Solidification and Recent Advancements

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued